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	 Condensation	 of	 2‐amino‐4‐chloro‐6‐methoxypyrimidine	 with	 aromatic	 aldehydes	 (2‐
hydroxy‐1‐naphthaldehyde,	3,4‐dihydroxybenzaldehyde	and	piperonal)	afforded	products	 in
good	 yields.	 The	 synthesized	 compounds	 (Schiff	 base	 of	 pyrimidine	 derivatives)	 were
screened	for	their	antibacterial	activity	against	Staphylococcus	aureus,	Escherichia	coli,	Bacillus
subtilis,	Klebsille,	Pseudomonas	aeruginosa	and	Salmonella.	Additionally,	the	compounds	were
tested	 for	 antifungicidal	 activity	 against	Candida	albicans,	Candida	 tropicalis	 and	Aspergillus
fumigatus.	 All	 compounds	 exhibited	 potent	 antibacterial	 and	 antifungal	 activity.	 Molecular
modeling	 studies	 were	 performed,	 showing	 the	 hydrogen	 bindings	 and	 hydrophobic
interactions.	
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1.	Introduction	
	
Pyrimidine	molecule	 is	 a	 promising	 structural	moiety	 for	
drug	designing,	which	form	a	component	in	a	number	of	useful	
drugs	 and	 are	 associated	 with	 many	 biological	 and	
therapeutically	activities	[1].		
The	 diverse	 array	 of	 biological	 and	 pharmacological	
activities	 of	 pyrimidines	 including	 antimicrobial	 [2‐5],	
antihypertensive	 [6],	 antitumor	 [7‐12],	 antiviral	 [13,14],	
anti‐HIV	 agents	 [15‐17],	 in	 addition	 to	 their	 cardiovascular	
[18,19]	 and	 diuretic	 [20,21]	 properties.	 Furthermore,	 some	
pyrimidines	were	used	as	hypnotic	drugs	 [22],	 in	 addition	 to	
their	activity	as	calcium‐sensing	receptor	antagonists	[23]	and	
as	 antagonists	 of	 the	human	A2A	 adenosine	 receptor	 [24]	 as	
well.	 Bacimethrin	 (4‐amino‐5‐(hydroxymethyl)‐2‐methoxy	
pyrimidine)	 (1)	 is	 a	 pyrimidine	 antibiotic	 which	 is	 active	
against	 several	 staphylococcal	 bacteria	 (Figure	1)	 [25,26].	On	
the	 other	 hand,	 methoprim,	 5‐(3,4,5‐trimethoxybenzyl)	
pyrimidine‐2,4‐diamine	 [27,28]	 is	 used,	 in	 combination	 with	
sulfamethoxazole,	 as	 a	 bacteriostatic	 antibiotic	 (trimoxazole)	
for	the	treatment	of	urinary	tract	infections	and	Pneumocystis	
jirovecii	 pneumonia	 [29].	 Gemcitabine	 (2),	 a	 pyrimidine	
antimetabolite,	 is	an	approved	drug	 in	 the	U.S.	 for	pancreatic	
cancer	and	also	in	combination	for	certain	lung	cancer	patients	
(Figure	 1)	 [30].	 Further,	monastrol	 [31]	 is	 another	model	 of	
pyrimidine	derivative	as	inhibitor	of	kinesin	Eg5	that	interact	
with	microtubuline	and	then	causes	mitotic	arrest	[32].		
	
 
Figure	1.	Some	potentially	active	pyrimidine	derivatives.	
	
Schiff	bases	attracted	much	interest	due	to	their	biological	
properties,	 especially	 those	 derived	 from	 heterocyclic	
analogues	and	possess	cytotoxic	[33],	antimicrobial	[34]	and		
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Scheme	1
	
	
other	activities.	Kalpesh	et	al.	[35]	have	reported	several	novel	
Schiff	 base	 derived	 from	 2‐amino‐4,6‐dimethoxypyrimidine	
with	variousaromatic	aldehydes.		
The	 present	 work	 describes	 the	 synthesis	 and	 biological	
activity	of	new	azomethine	compounds	derived	from	2‐amino‐
4‐chloro‐6‐methoxypyrimidine,	 in	 addition	 to	 their	molecular	
modeling	study.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
Melting	points	were	measured	by	 a	Philip	Harris	melting	
point	 apparatus	 and	 are	 uncorrected.	 The	 IR	 spectra	 were	
recorded	 in	 the	 range	 4000‐200	 cm‐1	 on	 a	 Pye‐Unicam	 SP3‐
300	 spectrometer	 using	 KBr	 discs.	 1H,	 13C,	 HSQC	 and	 HMBC	
NMR	spectra	were	measured	on	a	Bruker	spectrometer	at	600	
MHz	with	TMS	as	an	internal	reference.	
	
2.2.	Synthesis	
	
2.2.1.	General	procedure	for	the	synthesis	ofaryl‐1‐(4‐
chloro‐6‐methoxypyrimidin‐2‐yl)imine	derivatives	(7‐9)	
	
2‐Amino‐4‐chloro‐6‐methoxypyrimidin	 (3)	 (160	 mg,	 1.0	
mmol)and	aromatic	aldehydes	(1.1	mmol)	4‐6	were	dissolved	
in	absolute	ethanol	followed	by	addition	of	catalytic	amount	of	
glacial	acetic	acid	drop	wise	and	the	mixture	was	heated	under	
reflux	for	8	h.	The	reaction	mixture	was	then	cooled	in	an	ice	
bath	 and	 the	 crude	 product	 thus	 obtained	 was	 collected	 by	
filtration,	 further	 purified	 by	 recrystallization	 from	 ethanol	
(Scheme	1).	
1‐(((4‐Chloro‐6‐methoxypyrimidin‐2‐yl)imino)methyl)	
naphthalen‐2‐ol	 (7):	 From	 o‐hydroxy‐naphthaldehyde	4	 (189	
mg).	Yield:	242	mg	(77%).	M.p.:	214‐218	°C.	FT‐IR	(KBr,	,	cm‐
1):	 3400	 (OH),	 3070,	 3067	 (CH‐Aro.),	 2930	 (CH‐alip.),	 1631‐
1558	(C=C,	C=N).	1H	NMR	(600	MHz,	CDCl3,	δ,	ppm):	10.14	(s,	
1H,	CH=N),	8.71	(d,	1H,	J3',4'	=	8.0	Hz,	Harom.‐4'),	8.41	(d,	1H,	J7',8'	
=	8.0	Hz,	Harom.‐8'),	8.28	(d,	1H,	J5',6'	=	8.0	Hz,	Harom.‐5'),	8.24	(t,	
1H,	J6',7'	=	8.0	Hz,	Harom.‐7'),	8.08	(t,	1H,	J5',6'	=	8.0	Hz,	Harom.‐6'),	
8.03	 (s,	 1H,	 Hpyrimid.‐5),	 7.47	 (d,	 1H,	 Harom.‐3'),	 4.80	 (s,	 3H,	
OCH3).	 13C	NMR	 (150	MHz,	 CDCl3,	 δ,	 ppm):	 186.5	 (Cpyrimid.‐6),	
171.6	 (C‐OH),	 161.3	 (Cpyrimid.‐2	 +	 CH=N),	 157.3	 (Cpyrimid.‐4),	
133.8,	 129.5,	 129.1,	 127.1,	 126.9,	 125.0	 (Carom.),	 119.5	 (Carom.‐
8'),	109.8	(Cpyrimid.‐5),	102.8	(Carom.‐2'),	54.8	(OCH3).	
4‐(((4‐Chloro‐6‐methoxypyrimidin‐2‐yl)imino)methyl)	
benzene‐1,2‐diol	(8):	From	3,4‐dihydroxy‐benzaldehyde	5	(152	
mg).	Yield:	230	mg	(82%).	M.p.:	133‐136	°C.	FT‐IR	(KBr,	,	cm‐
1):	 3446	 (OH),	 3030‐3016	 (CH‐aro.),	 2958	 (CH‐alip.),	 1661‐
1587	 (C=C,	C=N).	 1H	NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	9.70	
(s,	1H,	CH=N),	7.28	(dd,	1H,	 J2',6'	=	2.0	Hz,	J5',6'	=	8.0	Hz,	Harom.‐
6'),	7.24	(d,	1H,	Harom.‐2'),	7.06	(br	s.,	2H,	Hpyrimid.‐5	+	OH),	6.91	
(d,	1H,	Harom.‐5'),	6.10	(s,	1H,	OH),	3.82	(s,	3H,	OCH3).	13C	NMR	
(150	MHz,	DMSO‐d6,	δ,	ppm):	171.4	(Cpyrimid.‐6),	163.4	(Cpyrimid.‐
4),	 160.3	 (Cpyrimid.‐2	 +	 CH=N),	 152.7	 (C4'.‐OH),	 146.4	 (C3'‐OH),	
129.3	 (Carom.‐1'),	 125.0	 (Carom.‐6'),	 116.0	 (Carom.‐2'	 +	 Carom.‐5'),	
115.0	(Cpyrimid.‐5),	54.1	(OCH3).	
N‐(Benzo[d][1,3]dioxol‐5‐ylmethylene)‐4‐chloro‐6‐methoxy	
pyrimidin‐2‐amine	(9):	From	piperonal	6	(165	mg).	Yield:	210	
mg	(72%).	M.p.:	192‐194	°C.	FT‐IR	 (KBr,	,	 cm‐1):	3425	(OH),	
3065‐3020	 (CH‐aromatic),	 2890	 (CH‐aliphatic),	 1660,1594	
(C=C,	C=N).	1H	NMR	(600	MHz,	DMSO‐d6,	δ,	ppm):	9.81	(s,	1H,	
CH=N),	7.54	(dd,	1H,	J2',6'	=	2.0	Hz,	J5',6'	=	8.0	Hz,	H.‐6'),	7.32	(d,	
1H,	H‐4'),	7.13	(d,	1H,	H‐7'),	6.17	(s,	1H,	Hpyrimid.‐5),	6.09	(s,	2H,	
CH2),	3.92	(s,	3H,	OCH3).	13C	NMR	(150	MHz,	DMSO‐d6,	δ,	ppm):	
171.4	(Cpyrimid.‐6),	163.4	(Cpyrimid.‐4),	160.3	 (Cpyrimid.‐2	+	CH=N),	
153.2	 (C‐7a'),	 148.9	 (C‐3a'),	 129.0	 (C‐5'	 +	C‐6'),	 109.0	 (C.‐7'),	
106.7	(C.‐4'),	102.8	(Cpyrimid.‐5),	94.7	(CH2),	54.1	(OCH3).	
	
3.	Results	and	discussion	
	
3.1.	Chemistry	
	
Treatment	 of	 2‐amino‐4‐chloro‐6‐methoxypyrimidine	 (3)	
with	three	aldehyde	derivatives	(2‐hydroxy‐1‐naphthaldehyde	
(4),	 3,4‐dihydroxybenzaldehyde	 (5)	 and	 piperanol	 (6)	 in	
ethanol	and	catalytic	amount	of	glacial	acetic	acid	under	reflux	
afforded	the	desired	imine	derivatives	7‐9	 in	77,	82	and	72%	
yield,	respectively	(Scheme	1).	
The	structure	of	compounds	7‐9	was	confirmed	by	the	1H,	
13C	and	2D	NMR	spectra.	In	the	1H	NMR	spectra	of	compounds	
7‐9,	 the	singlets	at	δ	10.14,	9.70	and	9.81	ppm	were	assigned	
for	 the	 imino	protons	(CH=N),	whereas	 the	signlets	at	δ	8.03,	
7.06	and	6.17	ppm,	were	 attributed	 to	H‐5	of	 the	pyrimidine	
ring,	 respectively.	 The	 aromatic	 protons	 were	 fully	 analyzed	
where	H‐3’,	H‐4’,	H‐5’	and	H‐6’	of	the	analogue	7	appeared	as	
doublets	at	δ	7.47	((J3’4’	=	8.0	Hz),	8.71,	8.28	(J5’,6’	=	8.0	Hz)	and	
8.08	 ppm,	 respectively.	 H‐7’	 appeared	 as	 a	 triplet	 at	 δ	 8.24	
ppm	(J6’,7’	=	8.0	Hz),	while	H‐8’	was	resonated	as	a	doublet	at	δ	
8.41	ppm	(J7’,8’	=	8.0	Hz).	Moreover,	the	aromatic	protons	H‐2’	
and	H‐5’	of	the	analogue	8	appeared	as	doublets	at	δ	7.24	(J2’,6’	
=	2.0	Hz)	and	6.91	ppm	(J5’,6’	=	8.0	Hz),	respectively.	H‐6’	of	the	
same	 analogue	 resonated	 as	 a	 doublet	 of	 doublets	 at	 δ	 7.28	
ppm,	 while	 the	 singlet	 at	 δ	 6.10	 ppm	 was	 attributed	 to	 the	
hydroxyl	group.	The	analogue	9	showed	two	doublets	at	δ	7.32	
(J2’,6’	=	2.0	Hz)	and	7.13	(J5’,6’	=	8.0	Hz)	ppm	were	assigned	for	
the	 aromatic	 protons	 H‐2’	 and	 H‐6’,	 respectively.	 H‐7’	
appeared	as	a	doublet	of	doublets	at	δ	7.54	ppm	(J2’,6’	=	2.0	Hz,	
J5’,6’	=	8.0	Hz),	while	the	methylene	protons	(CH2)	appeared	as	
a	 singlet	 at	 δ	 6.09	 ppm.	 The	 methoxy	 group	 at	 C‐6	 of	 the	
pyrimidine	ring	of	compounds	7‐9	was	resonated	as	singlets	at	
δ	4.80,	3.80	and	3.90	ppm,	respectively.	In	the	13C	NMR	spectra	
of	compounds	7‐9,	 the	 resonances	 at	δ	161.3	and	160.3	ppm	
were	assigned	for	the	pyrimidine	carbon	atom	2	together	with	
the	carbon	atom	of	the	 imino	group,	respectively.	The	carbon	
atoms	4	of	 the	analogues	7‐9	were	 resonated	at	 δ	157.7	and	
163.4	 ppm,	 respectively,	 while	 C‐5	 of	 the	 same	 scaffold	
appeared	at	δ	109.3,	115.0	and	102.8	ppm,	respectively.	C‐6	of	
the	pyrimidine	ring	appeared	at	δ	186.5,	171.4	and	171.4	ppm,	
respectively,	whereas	 the	methoxy	group	resonated	at	δ	54.8	
and	54.1	ppm,	respectively.		
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Table	1.	Antibacterial	activity	of	the	Schiff‐base	derivatives	of	pyrimidine.	
Compound		 Conc.,	µg/mL	 Diameter	of	inhibition	zone	in	mm	for	different	microbial	species	
S.	aureus	 E.	coli B.	cerus Salmonella Pseudomonas	 Klebsella
100	 200	 300	 100	 200	 300	 100	 200	 300	 100	 200	 300	 100	 200	 300	 100	 200		 300	
7	 ‐	 ‐	 ‐	 7	 10 15 8 10 12 ‐ 13 15 ‐ ‐	 ‐	 ‐	 ‐ ‐
8	 ‐	 ‐	 ‐	 6	 8 10 ‐ ‐ 10 ‐ 8 10 ‐ ‐	 ‐	 ‐	 ‐ ‐
9	 ‐	 ‐	 ‐	 ‐	 8 10 ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐	 ‐	 ‐	 ‐ 10
	
	
Table	2.	Antifungal	activity	of	the	Schiff‐base	derivatives	of	pyrimidine.	
Compound		 Conc.,	µg/mL		 	Diameter	of	inhibition	zone	in	mm	for	different	microbial	species	
C.	albicans	 C.	trobicalis A.	fumigates		
100	 200 300 100	 200 300 100		 200		 300
7	 ‐	 8	 11	 8	 10	 	12	 8	 	10		 	11	
8	 ‐	 ‐	 ‐ ‐ 8 10 ‐ 	6		 10
9	 ‐	 ‐	 ‐	 	8	 9	 	10	 ‐	 	‐		 	‐	
	
	
	
	
Figure	2.	JC,H	Correlations	in	the	HMBC	NMR	spectrum	of	compound	9.	
	
	
The	 aromatic	 carbon	 atom	 (C‐OH)	 of	 the	 analogue	 7	
appeared	at	δ	171.6	ppm,	while	 those	of	 the	analogue	8	(C4'.‐
OH),	 (C3'‐OH)	 were	 resonated	 at	 δ	 152.7,	 146.4	 ppm,	
respectively.	 Furthermore,	 the	 aromatic	 carbon	 atom	 C‐2’	 of	
compound	 7	 appeared	 at	 δ	 102.8	 ppm	 in	 addition	 to	 the	
resonances	at	the	regions	δ	133.8‐125.0	ppm	were	assigned	to	
the	rest	aromatic	carbon	atoms.	The	aromatic	carbon	atoms	C‐
1’	and	C‐6’	of	compound	8	appeared	at	δ	129.3	and	125.0	ppm,	
respectively,	 whereas	 C‐2’	 together	 with	 C‐5’	 of	 the	 same	
compound	 were	 resonated	 at	 δ	 116.0	 ppm.	 Compound	 9	
showed	resonances	at	δ	129.0	ppm	assigned	for	the	aromatic	
carbon	 atoms	 C‐1’	 together	 with	 C‐7’,	 while	 the	 signals	 at	 δ	
106.7,	 149.9,	 153.2	 and	 109.2	 ppm	 were	 attributed	 to	 the	
aromatic	carbon	atoms	C‐2’,	C‐2a’,	C‐5a’	and	C‐6’,	respectively.	
In	 addition,	 the	 methylene	 Carbon	 atom	 appeared	 at	 δ	 94.7	
ppm.	 Compound	9	 has	 been	 selected	 for	 further	 NMR	 study.	
The	 gradient‐selected	 1H,	 13C,	 HMBC	 NMR	 spectrum	 [36]	 of	
compound	 9	 revealed	 two	 1,2JC,H	 in	 addition	 to	 five	 1,3JC,H	
correlations.	 Thus,	 the	 imino	 proton	 (CH=N)	 at	 δ	 9.81	 ppm	
showed	 three	 1,3JC,H	 correlations:	 first	 one	 with	 C‐2	 of	 the	
pyrimidine	 ring	 at	 δ	 160.3	 ppm,	 the	 second	 correlation	with	
the	aromatic	carbon	atom	C‐6’	at	δ	129.0	ppm	and	the	last	one	
with	the	aromatic	carbon	atom	C‐4’	at	δ	106.7	ppm.	Two	1,3JC,H	
correlations	 between	 CH2	 protons	 at	 δ	 6.09	 ppm	 with	 C‐3a’	
and	 C‐7a’	 at	 δ	 148.9	 and	 153.2	 ppm,	 respectively,	 were	
observed.	 Furthermore,	 H‐5	 of	 the	 pyrimidine	 ring	 at	 δ	6.17	
ppm	showed	a	1,2JC,H	correlation	with	C‐4	of	the	same	ring	at	δ	
163.4	 ppm	 as	well	 as	 a	 1,2JC,H	 correlation	with	 C‐6	 at	 δ	171.4	
ppm	(Figure	2).	
	
3.2.	Antibacterial	and	antifungal	activity	
	
The	synthesized	compounds	7‐9	were	screened	in‐vitro	for	
their	 antibacterial	 activity	 against	 bacteria:	 Staphylococcus	
aureus,	 Escherichia	 coli,	 Bacillus	 cerius,	 Salmonella,	 Klebsella	
and	 Pseudomonas	 aeruginosa	 using	 the	 disc‐agar	 diffusion	
technique	[37].	Muller	Hinton	agar	was	used	as	culture	media	
for	antibacterial	activity.	The	antifungal	activities	were	tested	
against	 fungus:	 Candida	 albicans,	 Candida	 trobicalis	 and	
Aspergillus	 fumigates	 by	 diffusion	 method.	 Recommended	
concentrations	100,	200	and	300	μg/mL	of	the	test	samples	in	
DMSO	solvent	was	introduced	in	the	respective	method.	Petri	
plates	containing	20	mL	of	Mueller	Hinton	Agar	were	used	for	
all	the	used	bacteria.	Candida	albicans	strain	was	cultivated	in	
Sabouraud’s	dextrose	agar.	Sterile	Whatman	No.1	filter	paper	
disks	 (6	 mm	 in	 diameter)	 impregnated	 with	 the	 solution	 in	
dimethylsulfoxide	of	the	test	was	placed	on	the	Petri	plates.	A	
paper	 disc	 impregnated	 with	 DMSO	 was	 used	 as	 negative	
control.	 The	 plates	 were	 incubated	 for	 24	 h	 in	 the	 case	 of	
bacteria	 and	 72	 h	 for	 fungi	 at	 28	 °C.	 The	 inhibition	 zone	
diameters	 were	 measured	 in	 millimeters	 using	 a	 caliper	
vernia.	
The	results	of	the	antibacterial	activity	are	shown	in	Table	
1	 and	 antifungal	 activity	 is	 shown	 in	 Table	 2.	 It	 is	 observed	
that	 the	 activity	 of	 compounds	 increases	with	 an	 increase	 in	
the	concentration	of	the	solutions.	The	antibacterial	activity	of	
all	 synthesized	 compounds	 showed	 no	 activivity	 against	 S.	
aureusa	 and	 Pseudomonas	 but	 all	 compounds	 showed	 good	
antibacterial	 activity	 against	 E.	 coli	 and	 Salmonella	 for	
compound	7	and	8	compounds,	Table	1.	
The	 results	 of	 antifungal	 activity	 of	 all	 synthesized	
compounds	 showed	 good	 active	 against	 C.	 trobicalis.	
Compounds	 7	 and	 8	 showed	 moderate	 activity	 against	 A.	
fumigatus,	as	shown	in	Table	2.	
	
4.	Molecular	modeling	analysis	
	
The	molecular	docking	was	performed	using	SYBYL‐X	1.1	
and	 the	 docking	 results	 were	 shown	 by	 PyMOL	 [38].	 Our	
molecular	docking	analysis	of	the	new	analogues	based	on	the	
modeling	 study	 which	 was	 performed	 to	 understand	 the	
binding	 mode	 of	 these	 analogues	 with	 the	 aspartate	
aminotransferase	 (ATT)	 of	 E.	 coli	 [39]	 binding	 pocket	 (PDB	
code:	3DLG,	[40]).	
Compound	9	 has	 been	 selected	 for	 the	docking	modeling	
study,	 since	 its	 binding	 energy	 score	 ‐8.2,	 indicating	 a	
selectivity	of	substituted	olefinic	benzoate	in	its	binding	to	the	
enzyme	pocket	(Figure	3).	As	shown	in	Figure	3,	the	aromatic	
ring	of	compound	9	was	fitted	into	an	aromatic	rich	subpocket	
surrounded	by	the	aromatic	side	chains	of	Trp130,	in	addition	
to	 two	 hydrogen	 bondings.	 The	 pyrimidine	 backbone	 was	
located	 in	 the	 middle	 of	 the	 binding	 pocket,	 anchoring	 the	
oxygen	 atom	 of	 the	 methoxy	 group	 at	 C‐6	 in	 a	 favourable	
position	for	hydrogen	bonding	with	the	NH2	group	of	Arg280,		
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Figure	3.	Docked	conformation	of	compound	9.	Docked	conformation	of	compound	9	showing	two	hydrogen	bondings:	Arg280	with	oxygen	atom	of	methoxy	
group	 at	 C‐6	 of	 pyrimidine	 ring	 and	 Ser284	 with	 oxygen	 atom	 of	 piperonal	 ring.	 It	 exhibited	 also	 hydrophobic	 interaction	 between	 phenyl	 group	 of	 the	
pyrimidine	scaffold	moiety	and	Trp130	of	aspartate	transaminase	enzyme	residues	of	E.	coli.	
	
	
in	addition	to	a	hydrogen	bonding	between	the	oxygen	atom	of	
piperonal	 group	 with	 OH	 of	 Ser284	 of	 the	 aspartate	 amino	
transferase	 (AAT)	 enzyme.	 Overall,	 the	 combination	 of	
hydrophobic	interaction	and	‐stacking	appears	to	govern	the	
binding	of	compound	9	with	AAT	of	E.	coli.		
	
5.	Conclusion	
	
In	 conclusion,	 synthesis	 of	 new	 aryl	 1‐(4‐chloro‐6‐
methoxypyrimidin‐2‐yl)imine	 derivatives	 (7‐9)	 has	 been	
described.	 All	 the	 new	 synthesized	 compounds	 have	 been	
evaluated	for	their	antibacterial	as	well	as	antifungal	activities.	
Compounds	7	 exhibited	 potential	 activity	 against	B.	 cerius	 at	
100	g/mL	whereas	 the	 others	 analogues	 showed	moderate	
to	poor	activity.	In	addition,	compound	7	showed	a	moderate	
antifungal	activity	against	C.	trobicalis	and	A.	fumigates	at	100	
g/mL.	 Compound	 9	 has	 been	 selected	 for	 a	 molecular	
modeling	 study	 showing	 its	 binding	 to	 the	 aspartate	
aminotransferase	(ATT)	of	E.	coli	enzyme	pocket	through	two	
hydrogen	bondings	and	one	hydrophobic	interaction.	
	
Acknowledgement	
	
We	 are	 grateful	 to	 Miss	 Anka	 Friemel	 of	 Chemistry	
Department,	 University	 of	 Konstanz,	 Germany	 are	 highly	
acknowledged	for	the	NMR	experiments.	We	are	also	grateful	
to	 Departments	 of	 Physiology	 and	 Microbiology,	 College	 of	
Veterinary	Medicine,	Basrah	University,	Iraq	for	providing	the	
facilities.	
	
References	
	
[1]. Jain,	K.	S.;	Chitre,	T.	S.;	Miniyar,	P.	B.;	Kathiravan,	M.	K.;	Bendre,	V.	S.;	
Veer,	V.	S.;	Shahane,	S.	R.;	Shishoo,	C.	J.	Curr.	Sci.	2006,	90,	793‐803.	
[2]. Patel,	D.	H.;	Mistry,	B.	D.;	Desai,	K.	R.	Indian	J.	Hetero.	Chem.	2003,	13,	
179‐180.		
[3]. Bantawal,	 S.	 H.;	Manjathuru,	M.;	Mari,	 K.	 S.;	 Padiyath,	 K.	M.	Bioorg.	
Med.	Chem.	2006,	14,	2040‐2047.		
[4]. Sharma,	P.;	Rane,	N.;	Gurram,	V.	K.	Bioorg.	Med.	Chem.	Lett.	2004,	14,	
4185‐4190.		
[5]. Adnan,	A.	B.;	Hesham,	T.	Z.;	Sherif,	A.	F.;	Azza,	M.	B.	Eur.	J.	Med.	Chem.	
2003,	38,	27‐36.		
[6]. Russell,	R.	K.;	Press,	 J.	B.;	Rampulla,	R.	A.;	McNally,	 J.	 J.;	Falotico,	R.;	
Keiser,	J.	A.	J.	Med.	Chem.	1988,	31,	1786‐1793.		
[7]. Cocco,	 M.	 T.;	 Congiu,	 C.;	 Lilliu,	 V.	 Bioorg.	 Med.	 Chem.	 2006,	 14,	
366‐372.		
[8]. Heidelberger,	 C.;	 Chaudhuri,	 N.	 K.;	 Danneberg,	 P.;	 Mooren,	 D.;	
Griesbach,	 L.;	Duschinsky,	R.;	 Schnitzer,	 R.	 J.;	 Pleven,	E.;	 Scheiner,	 J.	
Nature	1957,	179,	663‐666.		
[9]. Beattie,	J.	F.;	Breault,	G.	A.;	Ellston,	R.	P.	A.;	Green,	S.;	Jewsbury,	P.	J.;	
Midgley,	C.	J.;	Naven,	R.	T.;	Minshull,	C.	A.;	Pauptit,	R.	A.;	Tucker,	J.	A.;	
Pease,	J.	E.	Bioorg.	Med.	Chem.	Lett.	2003,	13,	2955‐2960.		
[10]. Kimura,	H.;	Katoh,	T.;	Kajimoto,	T.;	Node,	M.;	Hisaki,	M.;	Sugimoto,	Y.;	
Majima,	T.;	Uehara,	Y.;	Yamori,	T.	Anticancer	Res.	2006,	26,	91‐97.		
[11]. Lagoja,	I.	M.	Chem.	Biodiver.	2005,	2,	1‐50.		
[12]. Dudhe,	 R.;	 Sharma,	 P.	 K.;	 Verma,	 P.;	 Chaudhary,	 A.	 J.	 Adv.	 Sci.	 Res.	
2011,	2,	10‐17.		
[13]. Yamazi,	Y.;	Takahashi,	M.;	Todome,	Y.	Proc.	Soc.	Exp.	Biol.	Med.	1970,	
133,	674‐677.		
[14]. Prichard,	M.	N.;	Quenelle,	D.	C.;	Hartline,	C.	B.;	Harden,	E.	A.;	Jefferson,	
G.;	Frederick,	S.	L.;	Daily,	S.	L.;	Whitley,	R.	J.;	Tiwari,	K.	N.;	Maddry,	J.	
A.;	Secrist,	 J.	A.;	Kern,	E.	R.	Antimicrob.	Agents	Chemother.	2009,	53,	
5251‐5285.		
[15]. Miyasaka,	 T.;	 Tanaka,	 H.;	 Baba,	 M.;	 Hayakawa,	 H.;	 Walker,	 R.	 T.;	
Balzarini,	J.;	De	Clercq,	E.	J.	Med.	Chem.	1989,	32,	2507‐2509.		
[16]. Tanaka,	H.;	Takashima,	H.;	Ubasawa,	M.;	Sekiya,	K.;	Nitta,	I.;	Baba,	M.;	
Shigeta,	 S.;	 Walker,	 R.	 T.;	 De	 Clercq,	 E.;	 Miyasaka,	 T.	 J.	Med.	 Chem.	
1992,	35,	337‐345.		
[17]. Balzarini,	 J.;	 Baba,	 M.;	 De	 Clercq,	 E.	 Antimicrob.	 Agents	 Chemother.	
1995,	39,	998‐1002.		
[18]. Fillios,	 L.	 C.;	 Naito,	 C.;	 Andrews,	 S.;	 Roach,	 A.	M.	Circ.	Res.	1960,	8,	
71‐77.		
[19]. Kappe,	C.	O.	Tetrahedron	1993,	49,	6937‐6963.		
[20]. Kreutzberger,	A.;	Burgwitz,	K.	Arch.	Pharm.	1981,	314,	394‐398.		
[21]. Monge,	A.;	Martinez‐Merino,	V.;	Sanmartin,	C.;	Fernandez,	F.	J.;	Ochoa,	
M.	C.;	Bellver,	C.	Artigas,	P.	Arznei‐Forschung.	1990,	40,	1230‐1233.		
[22]. Weitzel,	K.	W.;	Wickman,	J.	M.;	Augustin,	S.	G.;	Strom,	J.	G.	Clin.	Ther.	
2000,	22,	1254‐1267.		
[23]. Yang,	W.;	Ruan,	Z.;	Wang,	Y.;	Van	Kirk,	K.;	Ma,	Z.;	J.	Arey,	B.;	Cooper,	C.	
B.;	Seethala,	R.;	Feyen,	J.	H.	M.;	Dickson,	J.	K.	J.	Med.	Chem.	2009,	52,	
1204‐1208.		
[24]. Gillespie,	R.	 J.;	 J.	Bamford,	S.;	Botting,	R.;	Comer,	M.;	Denny,	S.;	Gaur,	
S.;	Griffin,	M.;	 Jordan,	A.	M.;	Knight,	A.	R.;	Lerpiniere,	 J.;	Leonardi,	S.;	
Lightowler,	S.;	McAteer,	S.	et	al.	V.	J.	Med.	Chem.	2009,	52,	33‐47.		
[25]. Tanaka,	 F.;	 Takeuchi,	 S.;	 Tanaka,	 N.;	 Yonehara,	 H.;	 Umezawa,	 H.;	
Sumiki,	Y.	J.	Antibiot.	1961,	14,	161‐162.		
[26]. Reddick,	 J.	 J.;	 Saha,	 S.;	 Lee,	 J.;	Melnick,	 J.	 S.;	 Perkins,	 J.;	 Begley,	 T.	 P.	
Bioorg.	Med.	Chem.	Lett.	2001,	11,	2245‐2248.		
[27]. Stenbuck,	P.;	Hood,	H.	M.	1962,	US	Patent	3,	049,	544.		
[28]. Brogden,	R.	N.;	Carmine,	A.	A.;	Heel,	R.	C.;	Speight,	T.	M.;	Avery,	G.	S	
Drugs	1982,	23,	405‐430.		
[29]. Hughes,	W.	T.;	 Feldman,	 S.;	 Sanyal,	 S.	K.	 T.	Can.	Med.	Assoc	 J.	1975,	
112,	47‐50.		
[30]. Hertel,	L.	W.;	Border,	G.	B.;	Kroin,	J.	S.;	Rinzel,	S.	M.;	Poore,	G.	A.;	Todd,	
G.	C.;	Grindey,	G.	B.	Cancer	Res.	1990,	50,	4417‐4422.		
[31]. Mayer,	T.	U.;	Kapoor,	T.	M.;	Haggarty,	S.	J.;	King,	R.	W.;	Schreiber,	S.	L.;	
Mitchison,	T.	J.	Science	1999,	286,	971‐974.		
[32]. Sharp,	D.	J.;	Rogers,	G.	C.;	Scholey,	J.	M.	Nature	2000,	407,	41‐47.		
[33]. Parikh,	K.	S.;	Vyas,	S.	P.	Asian	J.	Biochem.	Res.	2012,	2,	1‐7.		
[34]. Gulcan,	M.;	Sonmez,	M.;	Berber,	I.	Turk.	J.	Chem.	2012,	36,	189‐200.		
[35]. Kalpesh,	S.	P.;	Sandip,	P.	V.	der	Pharm.	Lett.	2012,	4,	638‐640.		
[36]. Davis,	A.	L.;	Keeler,	J.;	Laue,	E.	D.;	Moskau,	D.	J.	Magn.	Reson.	1992,	98,	
207‐216.		
[37]. Abraham,	E.	P.;	Chain,	C.	M.;	Fletcher,	A.	D.;	Gardner,	N.	G.;	Heatly,	M.	
A.	Jennings,	H.	W.	Lancet	1941,	238,	177‐1989.		
[38]. Seeliger,	S.;	de	Groot,	B.	L.	J.	Comput.	Aid.	Mol.	Des.	2010,	24,	417‐422.		
[39]. Onuffer,	 J.	 J.;	 Ton,	 B.	 T.;	 Kleent,	 I.;	 Kirsch,	 J.	 F.	Protein	 Sci.	1995,	4,	
1743‐1749.	
[40]. Zhan,	P.;	Liu,	X.;	Li,	Z.;	Fang,	Z.;	Pannecouque,	C.;	De	Clercq,	E.	Chem.	
Biodivers.	2010,	7,	1717‐1727.	
	
